ElectroCore plays musical execs before commercializing migraine treatment

Personnel

ElectroCore is doing some shuffling. Frank Amato has been bumped up to the CEO position after having served as chief operating officer for the Merck-backed med tech company.

The company--which offers non-invasive vagus nerve stimulation (nVNS) therapy--is in the midst of a Board-approved reorganization that is supposed “position the company for its next phase of growth,” ElectroCore explained in the announcement.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Amato has been COO at ElectroCore since he joined the company in 2012. He has worked on commercial elements in pharmaceuticals previously, including being the U.S. VP of specialty commercial operations at Merck. He has also held positions at Schering-Plough, Ligand Pharmaceutical and Pfizer.

Former CEO JP Errico, founder and board member, will become the chief science and strategy officer at ElectroCore and will work on developing nVNS to move into other therapeutic areas. Errico founded ElectroCore in 2005, and can boast about several successful ventures such as co-founding K2 Medical and Spine Core. The announcement noted that products Errico has patented, developed and commercialized account for over $12 billion in sales to date.

ElectroCore has plans to commercialize its gammaCore nVNS therapy for the treatment of cluster headache and migraine. These moves are part of an effort to continue the development of nVNS to treat other central nervous system disorders.

GammaCore therapy already has a CE mark and is being commercialized in Europe thanks to a partnership with Desitin, a CNS-focused pharma company.

While ElectroCore has regulatory approvals for gammaCore in treating cluster headaches and migraines in the EU, the FDA is still reviewing the treatment before approving it in the U.S.

- here's the release

Related Articles:
electroCore in talks with potential pharma partners
Neuro-stimulator startup electroCore secures Series A expansion to $50M

Read more on

Suggested Articles

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.

FDA staff took the action in response to cases of early growth plate closure in children on the retinoic acid receptor gamma agonist.

The CTAD presentation cleared up some questions about the data set without delivering a telling blow for either side of the debate.